ClinicalTrials.gg
RecruitingNCT06959706Updated Nov 2, 2026

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of TGW101 in Advanced Solid Tumors, sponsored by Tagworks Pharmaceuticals BV. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Tagworks Pharmaceuticals BV · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 403 studies in Carcinoma with a site in United States — 71 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Planned enrollment
119th of 359
90 · median 48
Started
2025
with 17 others
Phase 1
112 of 403
15 open now
Primary completion
2027-10
later than 53 of 109 live
Registered
380th of 403
by date

Among the 403 studies in Carcinoma with a site in United States, this one is the 119th largest by planned enrollment of the 359 interventional ones that give a count, is one of 18 that started in 2025, is one of 112 in phase 1, reaches primary completion later than 53 of the 109 other live ones, and was the 380th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

71 of the 403 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Antibody-drug conjugates
  • Carcinoma
  • TGW101
  • TGW101-ADC
  • TRG001
  • TAG-72
  • Cancer
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written prior to any study procedures.
  2. Males or females 18 years or older.
  3. or cytologically confirmed diagnosis of a solid tumor listed below and have evidence of disease progression on or after (within 3 months of discontinuation) the most recent treatment regimen:

    1. Endometrial cancer.
    2. Esophageal, adenocarcinoma only.
    3. Gastric/gastroesophageal junction (GEJ).
    4. Non-small cell lung cancer, adenocarcinoma only.
    5. Ovarian.
  4. disease, intolerance to, or documented refusal of available standard therapy(ies) known to provide clinical benefit for the participant's solid tumor malignancy per Investigator judgment.
  5. At least 1 per v1.1 except for participants with bone-only disease.
  6. pretreatment; if not possible, archival tissue block (preferred) or unstained formalin-fixed paraffin-embedded slides required.
  7. Performance Status 0-1.
  8. of > 3 months in the opinion of the Investigator.
  9. Adequate hepatic, hematologic, and renal function.

Exclusion criteria

Exclusion Criteria:

  1. Active second or history of another malignancy within the last 2 years, with the exception of: treated non-melanoma skin cancers; treated carcinoma in situ (e.g., breast and cervix); controlled superficial carcinoma of the urinary bladder; T1a or b carcinoma of the prostate; papillary thyroid carcinoma Stage I treated surgically for cure.
  2. Known symptomatic .
  3. Significant cardiovascular disease within 6 months prior to starting study drug.
  4. Evidence of an active systemic bacterial, fungal, or viral infection requiring treatment.
  5. Grade ≥ 2 peripheral neuropathy.
  6. Major surgery within 4 weeks prior to starting study drug.
  7. Prior solid organ or bone marrow progenitor cell transplantation.
  8. Prior high-dose chemotherapy requiring stem cell rescue.
  9. Anticancer therapy within 28 days or within 5 half-lives (whichever is shorter) prior to starting study drug.
  10. Palliative radiation therapy within 14 days prior to starting study drug.
  11. within 28 days prior to starting study drug.
  12. Pregnant or a breastfeeding postpartum female.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    TGW101: Dose Escalation Cohorts

    Escalating doses of TGW101-anti-drug conjugate (ADC) will be administered via intravenous (IV) infusion followed by administration of TRG001. The treatment period continues until a reason for permanent discontinuation of treatment occurs.

    Drug: TGW101

  • Experimental
    TGW101: Enrichment Cohorts

    During Dose Escalation, additional participants may be enrolled to permit further evaluation of TGW101 to support selection of the optimal recommended dosing regimen(s) for expansion (RDE\[s\]). At the discretion of the Safety Oversight Committee (SOC), enrollment in enrichment cohorts may be limited to specific tumor type(s) based on assessment of clinical activity by the Sponsor in the dose escalation portion, and other nonclinical, translational, and clinical data.

    Drug: TGW101

Interventions

  • DrugTGW101

    TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    Time frame: Up to approximately 10 months

  2. Number of Participants Experiencing Dose-limiting Toxicities (DLTs)

    Time frame: Up to Day 28

  3. Number of Participants Experiencing Cycle Delay

    Time frame: Up to approximately 10 months

  4. Number of Participants Experiencing Dose Reduction

    Time frame: Up to approximately 10 months

  5. RDE of TGW101

    Time frame: Up to approximately 10 months

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  2. Area Under the Concentration-time Curve From Time Zero to the end of the Dosing Interval (AUCtau) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  4. Maximum Concentration (Cmax) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  5. Trough Concentration (Ctrough) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  6. Time to Maximum Concentration (Tmax) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  7. Apparent Terminal Elimination Half-life (t1/2) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  8. Steady-state Volume of Distribution (Vss) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  9. Clearance (CL) of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  10. Accumulation Index of TGW101-ADC and TRG001

    Time frame: Up to approximately 10 months

  11. Overall Response Rate (ORR)

    Time frame: Up to approximately 10 months

  12. Duration of Response (DOR)

    Time frame: Up to approximately 10 months

  13. Progression-free Survival (PFS)

    Time frame: Up to approximately 10 months

  14. Overall Survival (OS)

    Time frame: Up to approximately 10 months

  15. Number of Participants Experiencing Antidrug Antibodies (ADAs) Against TGW101-ADC

    Time frame: Up to approximately 10 months

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2027, 29 months after the start.

Of 42 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's planned 29 months is below that.

Counting every sponsor, half of 71 studies reached it within 46 months; a quarter within 30 and three quarters within 92.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2026 → Oct 2027 and completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
May 7, 2025
Primary completionEst.
Oct 2027was Sep 2026
CompletionEst.
Dec 2027was Sep 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Oct 2027
Nov 2, 2026
Study completion
Sep 2027→Dec 2027
Nov 2, 2026
Enrollment
50→90
Nov 2, 2026
Eligibility
1 inclusion criterion added, 5 removed
What changed in the criteria
Inclusion criteria
  • RemovedHistologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below, with radiographic evidence of disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or for castration resistant prostate cancer (CRPC), Prostate Cancer Clinical Trials Working Group 3, after most recent treatment and locally advanced or metastatic disease at Screening:
  • RemovedBreast cancer (all subtypes).
  • RemovedCastrate-resistant prostate cancer.
  • RemovedCervical cancer.
  • AddedHistologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below and have evidence of disease progression on or after (within 3 months of discontinuation) the most recent treatment regimen:
  • RemovedNon-squamous cell carcinoma of the head and neck, e.g., salivary gland neoplasms, with the exception of adenoid cystic carcinoma.
Nov 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants Experiencing Dose-limiting Toxicities (DLTs)Up to Day 21 → Up to Day 28
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Sep 2026→Oct 2027
    Study completion Sep 2027→Dec 2027
    Enrollment 50→90
    Eligibility 1 inclusion criterion added, 5 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedHistologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below, with radiographic evidence of disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or for castration resistant prostate cancer (CRPC), Prostate Cancer Clinical Trials Working Group 3, after most recent treatment and locally advanced or metastatic disease at Screening:
    • RemovedBreast cancer (all subtypes).
    • RemovedCastrate-resistant prostate cancer.
    • RemovedCervical cancer.
    • AddedHistologically or cytologically confirmed diagnosis of a solid tumor malignancy listed below and have evidence of disease progression on or after (within 3 months of discontinuation) the most recent treatment regimen:
    • RemovedNon-squamous cell carcinoma of the head and neck, e.g., salivary gland neoplasms, with the exception of adenoid cystic carcinoma.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants Experiencing Dose-limiting Toxicities (DLTs)Up to Day 21 → Up to Day 28
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06959706
Lead sponsor
Tagworks Pharmaceuticals BV
Responsible party
Sponsor
First posted
May 6, 2025
Start date
May 7, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Tagworks Pharmaceuticals
Contact
clinicaltrials@tagworkspharma.com
Please email

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion